Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R
about
Present Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaUK guidelines for the management of bone sarcomasImmunotherapy of Childhood SarcomasOsteosarcoma: Current Treatment and a Collaborative Pathway to SuccessAdvances in the management of osteosarcomaReview of Osteosarcoma and Current ManagementImmunotherapy for Bone and Soft Tissue SarcomasSmall-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse ChemotherapeuticsGermline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through TankyrasesOsteosarcoma Overview.Treatment pathway of bone sarcoma in children, adolescents, and young adultsCollaborative Pediatric Bone Tumor Program to Improve Access to Specialized Care: An Initiative by the Lebanese Children's Oncology Group.EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatmentPrognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study.Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Follow-up practices for high-grade extremity Osteosarcoma.Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.How do you design randomised trials for smaller populations? A framework.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaEffectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trialsFuture directions in the treatment of osteosarcoma.Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.Sarcoma immunotherapy: past approaches and future directions.An update on chemotherapy for osteosarcoma.BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Novel insights and therapeutic interventions for pediatric osteosarcoma.Drugs in early clinical development for the treatment of osteosarcoma.A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.Osteosarcoma: lessons learned and future avenues.Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment.
P2860
Q26750631-D5260B93-8BE4-4CBE-8FCC-0E1EA05B7086Q26752425-BD8E9E0B-8EAF-4BC7-ABF8-53946E879B16Q26795369-275B60C7-7E94-4B06-B1BA-D517DDFB1147Q26797555-BBEA81F1-178F-4BA4-AA16-84EDFB0633EDQ28067644-9636D2A5-6567-4E9F-87FF-927146F43191Q28077590-69AA99E6-1714-47D9-A9BF-801F9DC10EE6Q28088363-0D23A672-F573-4F3C-80F5-A64B2107EB40Q29027136-38CCA45E-39E7-4C85-B09A-83FA0C84C908Q30235105-1143B71D-2433-432B-B185-CF73F0D52741Q33434899-C7CC7B0A-A33C-4CE7-95AA-8754F39F2F32Q33692066-4EFE3E9A-1218-484C-B35F-3A5C325043F1Q33715651-A32E3B23-BE3B-4798-A5B1-47F73497F306Q33725511-08C627C5-FBA9-4A23-92E9-731DBF064354Q33835657-43099D5C-3D6E-4D53-BA7B-86B45D31ACBCQ33859567-9FE35D8F-5436-4F3B-B140-6F73877D0861Q35005741-22303191-0A33-4B23-A162-9EF8F7279D65Q35138344-DE63E8DF-182F-4ECB-A85D-46E5C4192458Q35506606-C33F8B11-5982-465A-99A6-997877760A05Q35848126-F2084B44-DC89-4B80-95F1-852AAB077DEAQ35894540-B2223A31-EC70-47E5-95A4-5FF5F1E9A8FBQ36011314-7E1CF44B-66CF-45E5-9FA0-EA4738B929E2Q36078941-A86C0482-F9FA-411E-A9D4-1D0D94FC36B9Q36203629-C5C2417F-6B2A-4224-9EB0-30D1A92126C5Q36316518-3F56F00F-4EE2-453B-B8E6-7ADD02B4F558Q36327357-B1409A8B-E2B7-4EB1-BF65-6FB7A925A3B3Q36600800-26949C69-AD1B-4627-8E9C-8299B717DD79Q37362836-3CD09F54-1C23-4BF8-993F-CC78E82DE1F8Q37471124-9CD8AEE0-2F02-4B2B-87AE-4AD5C283C6C0Q37733317-BC2B53B5-84C6-4CD6-8CBF-0BB90C8E428EQ38207986-F0C60725-D149-48CC-A288-7247F0CE853DQ38619114-E558DC58-C65E-408E-9F4B-E577A63D9EAEQ38683340-50C26769-C5F3-44F9-AF8B-60AE637243DAQ38736352-7A7CFEBD-FB1E-4153-B6BB-046CB6E97C84Q38783252-A6EAB3F0-529B-4886-8611-F8C38A27E0F4Q38819276-EAC087D0-69A9-4515-A4B2-221B9DC722A6Q38955517-D9D1C19E-1CF8-4FCD-A2FF-8D2159AA8A67Q39086751-2BB23D91-000E-4343-A98E-CD271EB7F5E5Q39229404-850AA691-51D4-4E83-9D9C-23948FF7B611Q39341518-6FC60E38-8EF5-4B98-AC13-86777E668505Q40306627-0D38E773-CAEA-4C4B-8675-78461CD42511
P2860
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@ast
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@en
type
label
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@ast
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@en
prefLabel
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@ast
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@en
P2093
P2860
P50
P356
P1476
Methotrexate, Doxorubicin, and ...... esults of the EURAMOS-1 Good R
@en
P2093
Allen Goorin
Beatrice Seddon
Bernadette Brennan
Carol Morris
Catharina Dhooge
Ching C Lau
Claudia Deffenbaugh
Daniel Baumhoer
EURAMOS-1 investigators
G Douglas Letson
P2860
P304
P356
10.1200/JCO.2014.60.0734
P407
P577
2015-06-01T00:00:00Z